Amniotics

Kaare Engkilde, Ph.D., CEO

Lund, Sweden

(NASDAQ: AMNI)

Virtual Presentation
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital, the company is pioneering the harvesting and propagation of tissue specific neonatal mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stemcell-based therapies targeting diseases with high unmet needs. Amniotics is based in Sweden. 

www.amniotics.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions